Meta-Analysis
Copyright ©The Author(s) 2024.
World J Diabetes. May 15, 2024; 15(5): 1011-1020
Published online May 15, 2024. doi: 10.4239/wjd.v15.i5.1011
Figure 1
Figure 1 PRISMA flow diagram. DPP-4: Dipeptidyl peptidase-4; GDM: Gestational diabetes mellitus; GlP-1: Glucagon-like peptide-1; CVOTs: Cardiovascular outcome trials; T1DM: Type 1 diabetes mellitus.
Figure 2
Figure 2 Risk of overall infections for dipeptidyl peptidase-4 inhibitors treatment vs control. DPP-4: Dipeptidyl peptidase-4.
Figure 3
Figure 3 Risk of site-specific infections for dipeptidyl peptidase-4 inhibitors treatment vs control. A: Respiratory infections; B: Urinary tract infections; C: Abdominal and gastrointestinal infections; D: Skin structure and soft tissue infections; E: Bone infections; F: Bloodstream infection. DPP-4: Dipeptidyl peptidase-4.